申请人:Cell Therapeutics, Inc.
公开号:US06075029A1
公开(公告)日:2000-06-13
A new class of xanthine compounds, variously substituted at the 1, 3, 7 and 8 positions, is characterized by an ability to modulate the activity of key enzymes involved in drug metabolism. These compounds generally are useful in affecting drug metabolism and, particularly, in extending the circulating half-life of compounds that are metabolized via P-450-mediated pathways.
一类新的黄嘌呤化合物,在1、3、7和8位置各异取代,具有调节参与药物代谢的关键酶活性的能力。这些化合物通常对影响药物代谢有用,特别是在延长通过P-450介导途径代谢的化合物的循环半衰期方面。